Therapy decisions for the symptomatic patient with metastatic castration-resistant prostate cancer

Metastatic prostate cancer continues to kill approximately 30,000 men per year. Since 2010, five new therapeutic agents have been Food and Drug Administration (FDA) approved to treat metastatic castration-resistant prostate cancer (mCRPC). With the increasing number of therapies available to clinici...

Descripción completa

Detalles Bibliográficos
Autores principales: Markowski, Mark C, Pienta, Kenneth J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2015
Materias:
Invited Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4814966/
https://www.ncbi.nlm.nih.gov/pubmed/25865849
http://dx.doi.org/10.4103/1008-682X.150843

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4814966/
https://www.ncbi.nlm.nih.gov/pubmed/25865849
http://dx.doi.org/10.4103/1008-682X.150843

Ejemplares similares